Clinical trial · Interventional
Evaluation of the Sensitivity to Different Chemotherapy Regimens in Platinum-Partial Sensitive Recurrent Ovarian Cancer
Evaluation of the Sensitivity to Different Chemotherapy Regimens in Platinum-Partial Sensitive Recurrent Ovarian Cancer Based on 11 Gene Tests of Homologous Recombination Pathway
NCT04337632CI-TRIAL-00051153unknownPhase 3ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Multicenter, prospective, randomized studies.Evaluation of the sensitivity to different chemotherapy regimens in platinum-partial sensitive recurrent ovarian cancer based on 11 gene tests of homologous recombination pathway.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Ovarian Cancer | Malignant Ovarian Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Doxorubicin Hydrochloride Liposome Injection+carboplatin | Drug | — | UNRESOLVED |
| paclitaxel +carboplatin | Drug | Carboplatin/Paclitaxel Regimen | ALIAS |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- PP
- description
- Doxorubicin Hydrochloride Liposome Injection 25mg/m2, carboplatin AUC 5, day 1, intravenous drip, repeated every three weeks.
- interventionNames
- Drug: Doxorubicin Hydrochloride Liposome Injection+carboplatin
- type
- ACTIVE_COMPARATOR
- label
- TP
- description
- paclitaxel 175mg/m2, carboplatin AUC 5, day 1, intravenous infusion, repeated every three weeks.
- interventionNames
- Drug: paclitaxel +carboplatin
Primary outcomes (1)
- measure
- PFS(Progression-Free-Survival)
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: 1. age: 18-75 years old 2. PS score: ECOG 0 \~ 2 3. histopathologically confirmed primary high-grade serous adenocarcinoma or high-grade endometrioid adenocarcinoma of the ovary, fallopian tube or peritoneum; 4. the time interval between this recurrence and the last chemotherapy was 6-12 months; 5. evaluate the ability of bone marrow, liver, kidney, heart and other important organ functions to withstand chemotherapy; 6. expected survival over 3 months; 7. sign the informed consent. Exclusion Criteria: 1. brain metastasis or the presence of symptoms caused by brain metastasis; 2. serious complications; 3. acute inflammatory reaction; 4. other tumors; 5. a history of allergy to paclitaxel or polyropyridone liposomes;
References
Publications (0)
Data not yet available
No reference posted for this study.